Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-055 manufacturers

Filters

Filters

Filters , active

Country of origin : Japan

Clear all

None products found

pp-055

Injection

Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
For wet age-related macular degeneration (wet AMD), targeting abnormal choroidal neovascularization and retinal damage. Phase 2 clinical development. Modality: Anti-FGF2 RNA aptamer (chemically modified oligonucleotide therapeutic). Mechanism / Target: Selective inhibitor of fibroblast growth factor 2 (FGF2), a key driver of pathological angiogenesis, inflammation, and fibrosis in wet AMD. Aims to suppress VEGF-independent neovascular pathways that contribute to anti-VEGF resistance. Route / form: Intravitreal injection. Differentiation: Targets FGF2, a pathway not addressed by current anti-VEGF therapies. Potential to treat patients who respond poorly to anti-VEGF agents or who experience disease progression due to fibrosis.
Manufacturer #38604

A Japan-based biotech venture specializing in RNA aptamer drug discovery, with clinical-stage programs in ophthalmology and rare diseases. It leverages a proprietary aptamer-discovery platform and seeks global collaborations to bring next-generation nucleic-acid therapies to market.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.